Projektdatenbank
Sortierung
–
- –
- Fördersumme ↑
- Fördersumme ↓
- Beginn ↑
- Beginn ↓
- Ende ↑
- Ende ↓
- Titel ↑
- Titel ↓
Standort
–
- –
- Berlin
- Extern
- Greifswald
- Göttingen
- Hamburg/Kiel/Lübeck
- Heidelberg/Mannheim
- München
- RheinMain
Projektart
–
- –
- DZG Innovation Cluster
- Daten- und Probennutzung
- Digitale Technologien
- Exzellenzprogramm
- Innovation Cluster
- Internationale Kooperation
- Klinische Studie
- Kompetenznetze
- Kooperation mit Externen
- OMICs
- Shared Expertise (SE)
- Standortprojekt
- Translational Research Project
Topic
–
- –
- protein based therapy
- DNA/RNA based
- Health services/health systems research
- Inflammatory heart diseases
- Mechanisms in ischemia/reperfusion
- angiogenesis
- arteriosclerosis
- cardiac hypertrophy/remodeling
- cardiomyocyte function
- endothelial cells/vascular function
- genetics of cardiovascular diseases
- iPSC
- imaging
- inflammation/vascular inflammation
- miRNAS/IncRNA
- other arrhythmias
- platelet function/thrombosis mechanisms
- stem cells/cardiac regeneration
- vascular remodelling/altering
SE-Merkmal
–
- –
- SE-Anbieter
- SE-Partner
SE-Nummer
–
- –
Zeige Einträge 1–9/1701
| ID | 81X1100301 |
| Institution | Deutsches Herzzentrum Berlin |
| Projektleiter | Volkmar Falk |
| Standort | Berlin |
| Projektart | Klinische Studie |
| Fördersumme | 2007622.00€ 2.007.622,00 |
| Beginn | 2013-06-0101.06.2013 |
| Ende | 2024-06-3030.06.2024 |
end-stage heart disease, ventricular assist device (VAD)
https://vad.dzhk.de/
| ID | 81X1300102 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Projektleiter | Gerd Hasenfuß |
| Standort | Göttingen |
| Projektart | Klinische Studie |
| Fördersumme | 1731738.90€ 1.731.738,90 |
| Beginn | 2013-08-0101.08.2013 |
| Ende | 2027-12-3131.12.2027 |
heart failure, asymptomatic systolic dysfunction
This cohort study explores ways of predicting when decreased cardiac performance without symptoms will develop into a clinically manifest disease. In many patients, decreased cardiac performance is detected during routine examinations without the patient showing any of the typical symptoms, such as a reduction in exercise tolerance or shortness of breath. This hidden heart failure can be caused by high blood pressure, myocardial infarction or diseases of the heart muscle. Some 1,500 such patients are to be examined and followed over a period of at least five years at the DZHK partner sites and at other clinics.
Within the scope of the study, blood markers, results from imaging studies and genetic profiles will be analysed in relation to the patients state of health and development of clinical symptoms. The emerging patterns and regularities could be used in the future to help predict when symptoms of heart failure will appear. Then therapeutic measures could be taken to counter the development of symptoms. This is all the more important because heart failure generally progresses gradually and clinicians have so far not found a way to prevent further deterioration of the condition.
| ID | 81X1300103 |
| Institution | Georg-August-Universität Göttingen - Universitätsmedizin |
| Projektleiter | Tim Friede |
| Standort | Göttingen |
| Projektart | Klinische Studie |
| Fördersumme | 114959.00€ 114.959,00 |
| Beginn | 2013-10-0101.10.2013 |
| Ende | 2024-09-3030.09.2024 |
end-stage heart disease, ventricular assist device (VAD)
https://vad.dzhk.de/
| ID | 81X1400102 |
| Institution | Universitätsmedizin Greifswald |
| Projektleiter | Wolfgang Hoffmann |
| Standort | Greifswald |
| Projektart | Klinische Studie |
| Fördersumme | 311748.62€ 311.748,62 |
| Beginn | 2013-08-0101.08.2013 |
| Ende | 2019-12-3131.12.2019 |
hereditary cardiomyopathy, inflammatory cardiomyopathy, acute myocarditis
Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy.
This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.
| ID | 81X1500101 |
| Institution | Universitätsklinikum Heidelberg |
| Projektleiter | Hugo A. Katus |
| Standort | Heidelberg/Mannheim |
| Projektart | Klinische Studie |
| Fördersumme | 785702.72€ 785.702,72 |
| Beginn | 2013-08-0101.08.2013 |
| Ende | 2019-12-3131.12.2019 |
hereditary cardiomyopathy, inflammatory cardiomyopathy, acute myocarditis
Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy.
This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.
| ID | 81X1600203 |
| Institution | Klinikum der Universität München |
| Projektleiter | Reza Wakili |
| Standort | München |
| Projektart | Klinische Studie |
| Fördersumme | 474076.69€ 474.076,69 |
| Beginn | 2016-01-0101.01.2016 |
| Ende | 2021-06-3030.06.2021 |
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/
| ID | 81X1600501 |
| Institution | Deutsches Herzzentrum München |
| Projektleiter | Adnan Kastrati |
| Standort | München |
| Projektart | Klinische Studie |
| Fördersumme | 1085319.68€ 1.085.319,68 |
| Beginn | 2014-08-1818.08.2014 |
| Ende | 2021-12-3131.12.2021 |
ticagrelor, prasugrel, acute coronary syndrome, percutaneous coronary intervention
Cardiovascular diseases caused by a blockage or severe narrowing of the coronary artery fall into the category of acute coronary syndrome (ACS). ACS and the life-threatening disturbances of heart perfusion associated with it range from instable angina pectoris to myocardial infarction. Despite the fact that huge progress has been made in the treatment of ACS with the use of drugs that prevent blood clotting and targeted therapy, ACS-related morbidity and mortality remain high. In Germany, an estimated 350,000 new cases of ACS are diagnosed each year.
This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. It is designed to make a significant contribution to antithrombotic therapy in ACS patients so that clinical outcomes can be improved.
The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes. This is based on:
the possibility of pre-treatment independent of clinical presentation and coronary anatomy
consistently positive results in the sub-group of patients with conservative treatment strategy
potentially positive effects of ticagrelor as a result of its interaction with adenosine metabolism, which affects several genes
To test this hypothesis 4,000 ACS patients are to receive either ticagrelor or prasugrel over a 12-month period and a comparative analysis of the two active agents will be performed.
| ID | 81X1600601 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Projektleiter | Alexander Hapfelmeier |
| Standort | München |
| Projektart | Klinische Studie |
| Fördersumme | 13849.14€ 13.849,14 |
| Beginn | 2014-06-2727.06.2014 |
| Ende | 2021-10-3131.10.2021 |
ticagrelor, prasugrel, acute coronary syndrome, percutaneous coronary intervention
Cardiovascular diseases caused by a blockage or severe narrowing of the coronary artery fall into the category of acute coronary syndrome (ACS). ACS and the life-threatening disturbances of heart perfusion associated with it range from instable angina pectoris to myocardial infarction. Despite the fact that huge progress has been made in the treatment of ACS with the use of drugs that prevent blood clotting and targeted therapy, ACS-related morbidity and mortality remain high. In Germany, an estimated 350,000 new cases of ACS are diagnosed each year.
This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. It is designed to make a significant contribution to antithrombotic therapy in ACS patients so that clinical outcomes can be improved.
The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes. This is based on:
the possibility of pre-treatment independent of clinical presentation and coronary anatomy
consistently positive results in the sub-group of patients with conservative treatment strategy
potentially positive effects of ticagrelor as a result of its interaction with adenosine metabolism, which affects several genes
To test this hypothesis 4,000 ACS patients are to receive either ticagrelor or prasugrel over a 12-month period and a comparative analysis of the two active agents will be performed.
| ID | 81X1600603 |
| Institution | Klinikum rechts der Isar der Technischen Universität München |
| Projektleiter | Silvia Egert |
| Standort | München |
| Projektart | Klinische Studie |
| Fördersumme | 246021.00€ 246.021,00 |
| Beginn | 2016-01-0101.01.2016 |
| Ende | 2021-06-3030.06.2021 |
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/
Es wurden keine Einträge mit den angegebenen Suchkriterien gefunden
Zeige Einträge 1 bis 9 von 1701